RT @Sunonmyhip: Spending time with @NarjustFlorezMD & @StephenVLiu was a highlight of my summit experience. So grateful for their assistanc….

“Take the trips, take the chances, make every memory possible. Live, Laugh, Love & Never Give Up.” – Denise. In honoring John’s legacy, Denise reminds us love endures. Your legacy can carry forward too. 💙.👉 Create your free will:

Honored to join the @IASLC Lung Cancer Considered Podcast highlighting the 2025 ALK+ Summit. 🎧 Hear our board members share how advocacy & community shape the future of ALK+ research. 🔗 #ALKPositive #LungCancer #PatientAdvocacy

RT @GO2forLungCancr: We mourn the loss of our co-founder, Bonnie J. Addario, an extraordinary leader whose vision, strength, and generosity….

RT @Yvonne_Diaz_: Grateful to be on the board of @ALKPositiveinc & a co-founder of @OncogeneCancer w @Janclarkgirls. Also to collaborate w….

RT @NarjustFlorezMD: One of favorite episodes of all time! . Amazing group of people and an incredible mission! . Check this one out FOR SU….

Meet @OncogeneCancer Research. Co-founded by @Yvonne_Diaz_ & @Janclarkgirls, this patient-led charity is working to accelerate research across oncogene-driven lung cancers - because resistance to targeted therapies remains a reality. Read more 👉 #LCSM

RT @OncogeneCancer: We’ve launched the Patient Voices Podcast: Stories & Hope in Lung Cancer!. Our first episode features Kathrin, diagnose….

RT @OncogeneCancer: Being diagnosed w #cancer shouldn’t mean losing your rights at work. This session w solicitor Colin Davidson @ColeKhan….

RT @OncogeneCancer: Surgery isn’t usually offered for stage 4 #lungcancer. Steve, diagnosed w stage 4 ALK+ in 2020, believed it could help….

RT @DrJNaidoo: #ASCOSNO25 .Superb talk by @tmprowell @US_FDA on the Regulatory Perspectives on including patients with CNS disease in clini….

For ALK+ patients who have progressed after targeted therapy, a trial at Moffitt Cancer Center offers hope. This study explores an enhanced form of Tumor-Infiltrating Lymphocyte (TIL) therapy—empowering a pt’s immune cells to fight cancer. Learn more:

Rick from San José was diagnosed ALK+ in 2014. In 2023, he joined the NVL-655 trial—and he’s still going strong. His advice: ‘Always focus on what’s important: your family and friends.’ . Read his story, including tips for scanxiety ⬇️

RT @Yvonne_Diaz_: Survival rates for the deadliest cancers – including lung – are barely improving. “The gap between the best & worst surv….

RT @nuvalent: This morning, we reported our Q2 2025 financial results alongside recent pipeline & business achievements and anticipated mil….

They’ve lived 10+ years with ALK-positive cancer. That shouldn’t be rare—it should be the norm. This #MakeAWillMonth, create a legacy that fuels research, hope & a future for all ALK+ patients. Make your will free with @FreeWill ⬇️.👉

Many in the ALK+ community now start lorlatinib first line or later. Managing side effects can be challenging — patients need clear, practical info. Our VP Nancee Pronsati & Dr. Ken Culver co-authored a patient guide w leading KOLs. Learn more👇. . #LCSM

RT @wintrgrnbuffalo: $PLTR Community.Here is the video of the live panel I was part of at the @ALKPositiveinc Lung Cancer Summit in San Die….

RT @wintrgrnbuffalo: $PLTR Yesterday was World Lung Cancer Day. 🫁 I recently made a video for @ALKPositiveinc to inspire fellow ALK lung ca….

Greg is not only our board member, advocate, but a constant source of strength for our ALK+ community. We’re proud to work alongside @FoundationMedicine & others to raise awareness, advance research, & bring hope to everyone facing lung cancer. Thank you for standing with us 💙.